Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onset of Action of Chlorpheniramine in Allergic Rhinitis
NCT02722083Phase 2Terminated
- Sponsor
- Bayer
- Start
- May 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of chlorpheniramine in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Bayer. Primary endpoint: Time to the meaningful relief at 4 hours. Started May 2016; status: terminated.
02
Drugs
chlorpheniramine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT02722083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722083.